With ipilimumab (anti-CTLA-4) monotherapy, the most common adverse effect is colitis, whereas nivolumab and pembrolizumab (anti-PD-1) have been found to cause hypothyroidism, rash, and diarrhoea (more commonly than colitis). The gene discussed is PDCD1; the disease is colitis.